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Alzheimer’s disease (AD) is a major public
health problem affecting nearly 35 million
people worldwide with numbers projected
to rise to 115.4 million by 2050. Medicare
and Medicaid cost of AD is anticipated to
increase fourfold to approximately $ 600
billion in the next 40 years. AD is the only
cause of death among the top 10 causes that
has no prevention or cure (1, 2). AD causes
are not fully known and clinical drug trials
have a greater than 90% failure rate. There
is an urgent need to find accurate meth-
ods of early detection as well as effective
therapies before patients with AD develop
significant brain damage.
Clinical diagnosis of AD remains a
challenge since there are no validated
tests for an affirmative diagnosis and
dozens of conditions can mimic it. Hall-
marks of AD brain are numerous neurons
with neurofibrillary tangles of paired heli-
cal filaments (PHFs), straight filaments,
and extracellular deposits of β-amyloid as
the major component of senile (neuritic)
plaques in the brain. Definitive diagno-
sis of AD is made only after an autopsy
or biopsy. While AD is the most common
cause of dementia in the elderly, account-
ing for approximately 50–70% of cases,
many other causes of dementia can mimic
and overlap with AD clinical presenta-
tion.Vascular dementia, mixed dementia of
vascular and Alzheimer’s etiology, demen-
tia with Lewy bodies (DLB), and fron-
totemporal dementias are some examples
with overlapping clinical and diagnostic
features.
Clinical diagnosis of probable AD is
currently made by excluding other causes
using history, exam and labs, structural
imaging, and cognitive testing. However,
their accuracy is suboptimal. For example,
a clinical-autopsy correlative study of more
than 900 cases seen at leading academic
memory centers found that some 40% of
patients clinically diagnosed with non-AD
dementia had postmortem histopathology
consistent with AD (3). Likewise, nearly
30% of patients, who were thought to have
AD, clinically do not meet postmortem
pathologic criteria for AD (3). In recent
clinical drug trials of mild to moderate
AD, it is also estimated that about 30% of
patients did not have AD pathology thus
making it difficult to determine if failures
were due to ineffective drug versus diag-
nostic errors (4). There is a call for the
development and integration of pathologic
biomarkers into routine clinical evalua-
tion to establish revised diagnostic crite-
ria for clinical and preclinical AD. Such
markers may not only assist with an accu-
rate affirmative diagnosis of AD and dis-
ease staging, but may also accelerate drug
development (5).
Molecular imaging, specifically positron
emission tomography (PET), is a promis-
ing modality for early detection and disease
staging in Alzheimer’s patients. Recently
approved amyloid PET tracers (e.g., F-18
florbetapir, F-18 flutemetamol) can detect
cortical fibrillary β-amyloid (6). A nega-
tive amyloid scan substantially decreases
the odds of a person having AD and can
impact clinical decision making or treat-
ment. In at-risk subjects, a positive amy-
loid scan is associated with a threefold
greater risk of converting to dementia (7).
The limitations of amyloid imaging are
that amyloid plaques by themselves are
insufficient for a positive diagnosis of AD.
Thus, the advent of a PET taupathology
tracer may serve as a complimentary tool
to aid in affirmative diagnosis, as well as
in disease staging. Given the number of
tau-based therapies being developed, a tau-
PET tracer would also allow for a selec-
tion of pathology-positive individuals and
monitor the effectiveness of therapy.
PATHOPHYSIOLOGY OF TAU IN AD
Tau proteins result from a single
microtubule-associated protein tau
(MAPT) gene (chromosome 17q21) in
humans and were discovered in 1975.
Healthy neurons contain microtubules,
which serve as a support structure and
guide nutritional supplies. Tau protein
binds to the microtubules, promotes their
assembly, and stabilizes them. There are six
isoforms of tau protein in human brain tis-
sue, referred to as τ3L,τ3S,τ3,τ4L,τ4S,and
τ4. Each has a distinguishing feature, i.e.,
number of binding domains repeats (R),
of 31 or 32 amino acids in the C-terminal
part of tau protein and one (1N), two (2N),
or no inserts of 29 amino acids each in the
N-terminal portion of the molecule. Three
of the tau proteins (τ3L, τ3S, τ3) have
three (3R) binding domains repeats and
the rest of them (τ4L, τ4S, τ4) have four
(4R) binding domains repeats. Chemical
changes (namely hyperphosphorylation)
occur in tau protein in AD. It is theorized
that in a hyperphosphorylated state, they
begin to pair up with other threads of tau
into PHFs and tangle together, causing
disintegration of microtubules, collapse
of neuron’s transport system, and forma-
tion of extremely insoluble aggregates.
These changes are presumed to disrupt
neuronal communication and lead to cell
death (8).
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All six of the τ isoforms are identified
in a hyperphosphorylated state in PHFs
in the AD brain. There is approximately
a four to eightfold higher level of phos-
phorylated tau protein found in the AD
brain compared to that of age-matched
healthy brains. Alzheimer’s staging in post-
mortem brains by Heiko and Eva Braak
showed that neurofibrillary tangle, neu-
ropil thread, and neuritic plaque distrib-
ution varied widely within cortical archi-
tectonic units and from one individual to
another. Similar to amyloid plaques, neu-
rofibrillary tangles and neuropil threads
showed a characteristic distribution pat-
tern of growth in six stages (see Table S1
in Supplementary Material) from entorhi-
nal cortex to hippocampus to neocortex
(9, 10).
Neurofibrillary tangles are generated
intracellularly. However, when neurons die,
the only neurofibrillary tangles remains are
“ghost tangles”which are localized extracel-
lularly. Since many neurons die and leave
“ghost tangles,” they are a common finding
in AD patients which can occur in preclin-
ical stages (10, 11). Therefore, the ability
to identify and evaluate the severity of tau
pathology in the brain may further assist
affirmative diagnosis of AD and disease
progression staging (possibly even after
β-amyloid deposition plateaus)and offer
evaluation of potential anti-tau treatment
efficacy.
While neurofibrillary tangles are known
as relatively specific markers for AD, other
forms of aggregated tau abnormalities
are identified among different forms of
dementia, such as Pick bodies in Pick’s
disease, globose tangles in progressive
supranuclear palsy (PSP), and chronic
post-traumatic encephalopathy (CTE).
PET TAU TRACERS
The ideal PET tau tracer would have a
strong selective binding potential to PHFs
and phosphorylated tau over β-amyloid (β-
amyloid has higher concentration in dis-
eased brains), high permeability of blood–
brain barrier, low metabolism, and low
non-tau (non-target) binding to other CNS
receptors and tissues (e.g., white matter)
(12–15). To our knowledge, at least seven
tau pathology PET tracers have been devel-
oped and used in clinical studies: C-11
PBB3, F-18 THK-523, F-18 THK-5105, F-
18 THK-5117, F-18 T808, F-18 FDDNP,
and F-18 T807. Not all of these agents
provide the desired specific affinity to tau
tangles. For instance, F-18 FDDNP demon-
strates binding to both β-amyloid and tau
pathology (it was not designed as a specific
tau tracer but as a tracer for both patholo-
gies). Another tau-targeting radiotracer,
THK-523, had an uptake pattern in AD
patients that was not distinguishable from
healthy controls (12).
Preliminary data for another agent from
this group, F-18 TKH5105, an arylquino-
line derivative, have shown that this probe
selectively binds to pathological PHF tau-
deposition in living patients with AD,
and may differentiate diseased brains from
healthy controls. Patients with AD had high
retention of F-18 TKH5105 in the tempo-
ral cortex, an area that is known to have
high densities of neurofibrillary tangles in
AD population, compared to the cerebel-
lum. Healthy controls’ uptake in the infe-
rior temporal cortex was identical to the
activity in the cerebellum. TKH 5105 was
also observed to have in vitro binding to
glial tau pathology in corticobasal degener-
ation and PSP. Further studies are necessary
to determine if this particular agent will be
useful for imaging tauopathies other than
AD. The researchers did not report any
toxic events and observed a rapid entry of
this agent into the gray matter areas (13).
18F-AV-1451 [(F-18)T807] is in Phase 2
development as a diagnostic PET tracer for
in vivo imaging of tau aggregate pathol-
ogy in patients with AD and related
neurodegenerative diseases characterized
by the presence of tau pathology (Figure 1).
Hence, we discuss it here as a prototypic
FIGURE 1 | (A) Normal 18F-AV-1451 PET study illustrating a tau-PET scan
from an elderly cognitively normal subject (MMSE score of 30). No
abnormal uptake is demonstrated above diffuse background activity.
(B) Abnormal 18F-AV-1451 PET study illustrating a tau-PET scan images of a
subject with mild Alzheimer’s disease (MMSE score of 22). Unlike an
individual with normal cognition, there is abnormally increased radiotracer
uptake distributed in the temporal lobes bilaterally. Source: Duke
University.
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tracer. It is an F-18-labeled small molecule
that demonstrates high selective binding
and affinity (15 nM K d in brain slices and
0.7 nM in purified PHF-tau) to tau pro-
tein aggregates and relatively spares nor-
mal monomeric tau proteins in ex vivo
human brain. One preclinical investigation
of 18F-AV-1451 showed that brains with
significant tau tangles burden or in combi-
nation with β-amyloid (“tau-rich” brains)
had increased uptake of the radiotracer
in the gray matter. Healthy controls and
brains mostly containing β-amyloid (“tau-
poor” brains) did not demonstrate such
findings.
The results suggested that 18F-AV-1451
selectively bound to PHFs, and has very
weak or no affinity to the β-amyloid
accumulation: an approximately 29 times
greater difference was found between bind-
ing to tau aggregates compared to β-
amyloid in the gray matter of AD brains
(14).
This radiopharmaceutical decays via
positron emission to O-18 with half-life
of 110 min. 18F-AV-1451 is administered
intravenously with a dose of up to 10 mCi
(370 MBq) for a whole body effective dose
of 8.92 mSv. Several preliminary studies
with AV-1451 have been presented at scien-
tific meetings and several Phase 2 trials in
AD, CTE, and other tauopathies are ongo-
ing. To date, several dozen AD and control
subjects have been studied (Figure 1) with-
out any significant serious safety concerns.
18F-AV-1451 had no significant distribu-
tion in the normal brain showing only a
diffuse pattern of background activity in
healthy controls, unlike brain in patients
with high probability of AD, with regional
distinct areas of uptake in the gray mat-
ter (14). In another analyses of 40 subjects
with normal or abnormal cognition, worse
memory performance was associated with
greater PET tau binding in the entorhinal
cortex.
Further data from multicenter studies
will soon clarify the clinical value of com-
bining information from both amyloid and
tau-PET scans. The cost of performing two
PET scans (amyloid and tau scan) and risks
(radiation exposure, incorrect interpreta-
tion) will need to be weighed against the
potential benefits. Tau imaging is also likely
to be included in several Phase 2 and 3
drug trials of tau-targeted therapeutics in
development and such studies will inform
us about its value as a therapeutic bio-
marker.
In summary, tau-PET imaging repre-
sents a significant new advance for the field
and it is hoped that the combination of tau
positive and amyloid positive PET scans,
along with the clinical presentation, may in
the future move us closer to an affirmative
in vivo diagnosis of AD. Tau scans may also
enhance diagnosis and testing of tau-based
therapies in FTD and CTE, and the results
of controlled trials testing its effects on
outcomes and cost of care will more defin-
itively guide its role in the clinical work up
of people with memory problems.
SUMMARY
18F-AV-1451 is one of several new investi-
gational PET radiopharmaceuticals under
study for in vivo imaging of tau pathol-
ogy in patients with AD. The primary
data show its high selectivity for binding
to tau protein aggregates vs. β-amyloid in
human brain tissue. Also, the first reports
show its favorable kinetics, rapid deliv-
ery into the brain, and clearance from
the white matter. It demonstrates very
low non-specific binding in white matter
as well as cortical gray matter of healthy
subjects. Subjects with different dementia
severity showed different patterns of radio-
tracer accumulation both in density and
anatomical spread, potentially reflective of
pathological Braak staging of tau deposit
patterns.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this
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